Road Town, Tortola, British Virgin Islands, Feb. 10, 2026 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) (the “Company”), a global leader in hyperscaling Telegram’s 1 billion users globally through vertically integrating software, middleware and confidential AI infrastructure designed for the Telegram super-app, today announced changes to the Company’s Board of Directors. The Company’s Board of Directors has unanimously approved the election of F. Daniel Siciliano as a new independent director, e ...

Core Insights - AlphaTON Capital Corp. is positioning itself as a key player in the Telegram economy, focusing on various strategic initiatives including acquisitions and investments in technology and healthcare sectors [1][2]. Company Overview - AlphaTON Capital Corp. is a technology public company listed on Nasdaq under the ticker symbol "ATON," targeting an addressable market of 1 billion monthly active users on Telegram [2][3]. - The company employs a comprehensive M&A and treasury strategy that includes direct token acquisition, validator operations, and strategic ecosystem investments to ensure sustainable returns for shareholders [2]. Recent Developments - Recent moves by AlphaTON include acquiring Forbes, investing in GPU infrastructure for Telegram's Cacoon AI network, and pursuing the gaming platform GAMEE [1]. - The company is also focused on tokenizing healthcare and cancer research, indicating a diversification of its investment strategy [1]. Leadership - The leadership team includes CEO Brittany Kaiser, Executive Chairman and Chief Investment Officer Enzo Villani, and Chief Business Development Officer Yury Mitin, who guide the company's strategic direction [2][5]. Industry Engagement - AlphaTON Capital is involved in network validation and staking operations, development of Telegram-based applications, and investments in TON-based decentralized finance protocols and gaming platforms [2]. - The company is also advancing therapies targeting checkpoint resistance pathways in drug development, aiming to improve patient quality of life [3].